Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Study of KHN922 for Injection to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity in Patients With Advanced Solid Tumors

NCT07514975 is registered in ClinicalTrials.gov with Chengdu Kanghong Biotech Co., Ltd. as lead sponsor.

NCT NCT07514975
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07514975 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Study of KHN922 for Injection to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity in Patients With Advanced Solid Tumors
Lead sponsor
Chengdu Kanghong Biotech Co., Ltd.
Phase
Phase 1/2
Overall status
Not yet recruiting
Start date
April 30, 2026
Completion date
April 30, 2029
Enrollment
276 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumors cancer